Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study - PubMed
4 hours ago
- #combination therapy
- #type 2 diabetes
- #real-world evidence
- The study evaluates the effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared to SGLT-2 inhibitor monotherapy in type 2 diabetes patients.
- A prevalent new-user cohort design was used with nationwide health claims data, matching patients on hybrid exposure sets and time-conditional propensity scores.
- Combination therapy showed a 29% lower hazard of all-cause mortality (HR 0.71, 95% CI 0.63-0.80) compared to SGLT-2 inhibitor monotherapy.
- Secondary outcomes, including a modified cardiovascular composite and heart failure, also showed hazard reductions with combination therapy.
- The findings suggest sustained concurrent use of both drug classes may offer clinical benefits, though residual confounding cannot be excluded.